ERBB2 and non-small cell lung carcinoma: Although Pan-HER TKIs such as afatinib, dacomitinib, and pyrotinib have demonstrated systemic efficacy in HER2-mutant NSCLC, their impact on the CNS remains unclear due to limited available data.